APLT News and Press, Applied Therapeutics Inc. From 10/31/22

Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodeling Baseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as ...

ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placebo Primary study endpoint is cardiac functional capacity (measured by Peak VO 2 ...

Are These Penny Stocks To Buy Right Now Or Avoid Entirely? If you’re looking for penny stocks to buy right now, this article discusses three companies that Wall Street analysts have hefty expectations for. While these are some of the most volatile types of companies to trade,...

Best Penny Stocks To Buy According To Insiders On their own, penny stocks are some of the most volatile and carry some of the biggest potential for significant gains quickly. Over the last few months, traders have seen explosive gains upward of thousands of percentage points. This isn&#...

• The study did not yet reach statistical significance at 12 months of treatment; however, AT-007 (gavorostat) demonstrated a trend in clinical benefit vs. placebo • Applied Therapeutics plans to meet with the EMA to discuss potential submission of the current data pac...

Save Foods ( SVFD ) -35% on pricing of $4.8M stock offering . Albireo Pharma ( ALBO ) -23% on Q2 earnings release . Tremor International ( TRMR ) -17% on Q2 earnings release . GAN ( GAN ) -17% on Q2 earnings release . Hel...

Turquoise Hill Resources ( TRQ ) -18% after Turquoise Hill rejects Rio Tinto's bid to take control of huge Mongolia mine . Arcadia Biosciences ( RKDA ) -18% to raise $5M in securities offering . Root ( ROOT ) -17% . TREASURE GLOBAL ( TGL ...

Applied Therapeutics press release ( NASDAQ: APLT ): Q2 GAAP EPS of -$0.96 misses by $0.40 . Cash and cash equivalents and short-term investments totaled $67.7 million as of June 30, 2022, compared with $80.8 million at December 31, 2021. For further details see:...

Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multip...

Gold sponsor of the 2022 Galactosemia Foundation Conference; new website and educational resources as part of ongoing commitment to the Galactosemia community Applied Therapeutics to present research and clinical update NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Applied...